Cargando…
Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report
It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance...
Autores principales: | , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Lippincott Williams & Wilkins
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/ https://www.ncbi.nlm.nih.gov/pubmed/36206106 http://dx.doi.org/10.1097/CAD.0000000000001402 |
_version_ | 1785019334574211072 |
---|---|
author | Zhao, Weichao Zhu, Minli Wang, Ruijuan Tong, Zhaohui |
author_facet | Zhao, Weichao Zhu, Minli Wang, Ruijuan Tong, Zhaohui |
author_sort | Zhao, Weichao |
collection | PubMed |
description | It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance achieving long survival with a median PFS of 46 months. A 52-year-old female diagnosed with stage IV lung adenocarcinoma was tested for no targeted drug benefit in the driver gene. The patient was financially disadvantaged and could not afford and refused immune checkpoint inhibitor drugs but was in the favor of platinum-based double-drug chemotherapy. After six cycles of effective administration of cisplatin in combination with pemetrexed, pemetrexed monotherapy was given for long-term maintenance treatment to date, with a median PFS of 46 months, with a treatment effect close to complete response and tolerable side effects. |
format | Online Article Text |
id | pubmed-10072206 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Lippincott Williams & Wilkins |
record_format | MEDLINE/PubMed |
spelling | pubmed-100722062023-04-05 Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report Zhao, Weichao Zhu, Minli Wang, Ruijuan Tong, Zhaohui Anticancer Drugs Case Reports It is relatively rare to achieve a median progression-free survival (PFS) of 40 months with pemetrexed monotherapy maintenance, especially in patients with advanced and severe lung cancer. Here, we reported a case of advanced severe lung adenocarcinoma treated with pemetrexed monotherapy maintenance achieving long survival with a median PFS of 46 months. A 52-year-old female diagnosed with stage IV lung adenocarcinoma was tested for no targeted drug benefit in the driver gene. The patient was financially disadvantaged and could not afford and refused immune checkpoint inhibitor drugs but was in the favor of platinum-based double-drug chemotherapy. After six cycles of effective administration of cisplatin in combination with pemetrexed, pemetrexed monotherapy was given for long-term maintenance treatment to date, with a median PFS of 46 months, with a treatment effect close to complete response and tolerable side effects. Lippincott Williams & Wilkins 2023-06 2022-10-06 /pmc/articles/PMC10072206/ /pubmed/36206106 http://dx.doi.org/10.1097/CAD.0000000000001402 Text en Copyright © 2022 The Author(s). Published by Wolters Kluwer Health, Inc. https://creativecommons.org/licenses/by-nc-nd/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution-Non Commercial-No Derivatives License 4.0 (CCBY-NC-ND) (https://creativecommons.org/licenses/by-nc-nd/4.0/) , where it is permissible to download and share the work provided it is properly cited. The work cannot be changed in any way or used commercially without permission from the journal. |
spellingShingle | Case Reports Zhao, Weichao Zhu, Minli Wang, Ruijuan Tong, Zhaohui Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
title | Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
title_full | Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
title_fullStr | Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
title_full_unstemmed | Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
title_short | Pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
title_sort | pemetrexed long-term maintenance therapy for advanced severe lung cancer with long-term progression-free survival: a case report |
topic | Case Reports |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10072206/ https://www.ncbi.nlm.nih.gov/pubmed/36206106 http://dx.doi.org/10.1097/CAD.0000000000001402 |
work_keys_str_mv | AT zhaoweichao pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport AT zhuminli pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport AT wangruijuan pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport AT tongzhaohui pemetrexedlongtermmaintenancetherapyforadvancedseverelungcancerwithlongtermprogressionfreesurvivalacasereport |